Can intravenous fosfomycin be used to treat multidrug-resistant Klebsiella infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Intravenous Fosfomycin for MDR Klebsiella

Yes, intravenous fosfomycin can be used for multidrug-resistant Klebsiella infections, but it should be used as part of combination therapy rather than monotherapy, particularly for severe infections.

Guideline-Based Recommendations

The 2022 ESCMID guidelines provide clear direction for fosfomycin use in carbapenem-resistant Enterobacterales (CRE), which includes MDR Klebsiella 1:

For Severe Infections

  • When newer agents are unavailable or the organism is resistant to them: Fosfomycin should be used in combination with at least one other active drug (conditional recommendation, moderate evidence) 1
  • The guidelines explicitly state: "For patients with severe infections caused by CRE susceptible in vitro only to polymyxins, aminoglycosides, tigecycline or fosfomycin, or in the case of non-availability of new BLBLI, we suggest treatment with more than one drug active in vitro" 1

For Non-Severe Infections

  • Fosfomycin monotherapy may be considered on an individual basis, particularly for urinary tract infections, according to the source of infection 1

Critical Caveat

The guidelines note there is insufficient evidence to recommend for or against fosfomycin monotherapy for CRE at the time of publication 1. This underscores the importance of combination therapy for severe disease.

FDA Label Information

The FDA label confirms fosfomycin has in vitro activity against Klebsiella species 2:

  • Klebsiella pneumoniae and Klebsiella oxytoca show MICs ≤64 mcg/mL in ≥90% of strains
  • However, the label explicitly states: "the safety and effectiveness of fosfomycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials" 2

Supporting Clinical Evidence

Recent real-world data supports fosfomycin use in MDR Klebsiella:

High-Quality Recent Studies

The 2024 ICU study by 3 provides the strongest evidence:

  • FOS-containing regimens showed significantly higher clinical cure (89.2% vs 65.9%, p=0.017)
  • Lower 30-day mortality (13.5% vs 34.2%, p=0.039)
  • This effect was particularly evident for KPC-producing Klebsiella pneumoniae
  • Fosfomycin was independently associated with survival (HR=0.29,95%CI 0.09-0.93)

Infection-Specific Efficacy

A 2023 study 4 demonstrated variable response rates by infection type:

  • Urinary tract infections: 92.3% clinical response (excellent)
  • Bacteremia: 72.2% response (good)
  • Pneumonia: 56.0% response (moderate)
  • Overall 30-day mortality was 33%

UTI-Specific Data

For KPC-producing Klebsiella UTIs specifically, a 2025 study 5 showed:

  • 70.2% clinical cure at day 21
  • Importantly, in vitro susceptibility testing did not predict clinical outcomes
  • High-dose IV fosfomycin was effective regardless of susceptibility results

Practical Algorithm

Step 1: Assess Infection Severity

  • Severe infection (septic shock, ICU-level illness, pneumonia, bacteremia): Mandatory combination therapy
  • Non-severe infection (uncomplicated UTI, stable patient): Consider monotherapy

Step 2: Choose Combination Partner

Based on susceptibility and availability:

  1. First-line: Newer beta-lactam/beta-lactamase inhibitors (ceftazidime-avibactam, meropenem-vaborbactam) if active 1
  2. Second-line: Meropenem (if MIC ≤8 mg/L, use high-dose extended infusion) 1, 6
  3. Third-line: Polymyxins, aminoglycosides, or tigecycline if active 1

Step 3: Dosing

  • Use high-dose IV fosfomycin (typically 6-8 g every 8 hours for severe infections) 5, 4

Important Caveats

Safety Monitoring

Common adverse events require monitoring 4:

  • Hypokalemia (37.2%): Check potassium frequently, was associated with increased 14-day mortality 7
  • Hypernatremia (22.3%): Monitor sodium levels
  • Both are generally mild and manageable

Resistance Concerns

  • Relapse with fosfomycin resistance occurs in 22.9-29% of cases 8
  • This reinforces the critical importance of combination therapy to suppress resistance emergence 6
  • Pharmacodynamic data shows meropenem addition dramatically suppresses fosfomycin resistance development 6

Limitations

  • Do not use fosfomycin monotherapy for severe infections - the evidence consistently shows combination therapy is superior 1, 3
  • For pneumonia and bacteremia, expect more modest response rates compared to UTIs 4
  • The 2024 study showing mortality benefit was in critically ill patients receiving combination therapy 3

References

Related Questions

What is the recommended duration of fosfomycin therapy for infections caused by extended‑spectrum β‑lactamase (ESBL)‑producing organisms?
What is the recommended intravenous fosfomycin dosing for adults (including adjustments for renal impairment) and for pediatric patients?
What is the recommended meropenem dosing for a Klebsiella infection and what alternative agents should be used if the isolate is resistant to meropenem?
What meropenem dose and treatment duration should be used for a Klebsiella infection in an adult, including adjustments for impaired renal function?
Can laxatives be used in diverticulitis, and which types are safe to use?
How should a patient with a reported tetanus allergy be managed after receiving a Tdap (tetanus, diphtheria, pertussis) vaccine?
Should I have my coagulation status monitored while taking a blood thinner?
Is fluconazole excreted by the liver or the kidneys?
What does an elevated red cell distribution width (RDW) with a high platelet count indicate, and how should it be evaluated and managed?
What is the recommended prednisone tapering schedule for a patient with rheumatoid arthritis who is initiating disease-modifying therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.